| Monday, October 21, 2013, Day One |
| 10:15 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 5-6 |
Key Ballroom 8,11,12 |
| Session Title |
TRA1. TOP-RANKED ABSTRACTS, CONCURRENT SESSION 1
Click to view session |
TRA2. TOP-RANKED ABSTRACTS, CONCURRENT SESSION 2
Click to view session |
| 10:15 - 10:30 |
TRA1-1* (MET) COMPARISON OF CONTROL ALGORITHMS FOR..
TRA1-1* (MET) COMPARISON OF CONTROL ALGORITHMS FOR SCHEDULING TESTING VISITS
|
TRA2-1 (DEC) FOLLOW THE CROWD: HOW SOCIAL MEDIA COMMENTS ON..
TRA2-1 (DEC) FOLLOW THE CROWD: HOW SOCIAL MEDIA COMMENTS ON HEALTH NEWS ARTICLES INFLUENCE OPINIONS ABOUT HEALTH CHOICES
|
| 10:30 - 10:45 |
TRA1-2* (HSP) MODELLING TO SUPPORT REVISED WHO HIV TREATMENT..
TRA1-2* (HSP) MODELLING TO SUPPORT REVISED WHO HIV TREATMENT GUIDELINES: CHALLENGES OF SYNTHESIZING RESULTS ACROSS MULTIPLE MODELS
|
TRA2-2 (DEC) RANDOMIZED TRIAL OF AN INFORMED FREE CHOICE..
TRA2-2 (DEC) RANDOMIZED TRIAL OF AN INFORMED FREE CHOICE APPROACH TO PRENATAL TESTING AMONG WOMEN OF VARYING LITERACY LEVELS
|
| 10:45 - 11:00 |
TRA1-3 (HSP) IMPACT OF INCREASING WAIT TIMES ON THE..
TRA1-3 (HSP) IMPACT OF INCREASING WAIT TIMES ON THE EFFECTIVENESS OF TRANSCATHETER AORTIC-VALVE REPLACEMENT (TAVR) IN HIGH-RISK AND INOPERABLE PATIENTS WITH SEVERE AORTIC DISEASE: A DISCRETE EVENT SIMULATION MODEL
|
TRA2-3 (DEC) I'M BIASED: INCREASED PATIENT COMPLIANCE WHEN..
TRA2-3 (DEC) I'M BIASED: INCREASED PATIENT COMPLIANCE WHEN SURGEONS ADMIT SPECIALTY BIAS
|
| 11:00 - 11:15 |
TRA1-4* (HSP) INCREMENTAL BENEFITS AND COST-EFFECTIVENESS OF..
TRA1-4* (HSP) INCREMENTAL BENEFITS AND COST-EFFECTIVENESS OF A CATCH-UP HPV VACCINATION PROGRAM IN NORWAY
|
TRA2-4* (DEC) THE IMPORTANCE OF SHARED DECISION MAKING TO..
TRA2-4* (DEC) THE IMPORTANCE OF SHARED DECISION MAKING TO PATIENTS SELECTING A SPECIALIST FOR CONSULTATION
|
| 11:15 - 11:30 |
TRA1-5 (DEC) EFFICACY OF THE BRCA GIST INTELLIGENT TUTORING..
TRA1-5 (DEC) EFFICACY OF THE BRCA GIST INTELLIGENT TUTORING SYSTEM TO HELP WOMEN DECIDE ABOUT TESTING FOR GENETIC BREAST CANCER RISK
|
TRA2-5 (DEC) CLINICAL BENEFITS OF CONTRALATERAL PROPHYLACTI..
TRA2-5 (DEC) CLINICAL BENEFITS OF CONTRALATERAL PROPHYLACTIC MASTECTOMY FOR WOMEN WITH UNILATERAL EARLY-STAGE BREAST CANCER
|
| 1:00 - 2:15 PM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 5-6 |
Key Ballroom 8,11,12 |
Key Ballroom 7,9,10 |
| Session Title |
A. ESTIMATING COSTS IN A COMPLEX HEALTHCARE ENVIRONMENT
Click to view session |
B. INCORPORATING PATIENT AND PHYSICIAN PREFERENCES IN MEDICAL DECISION MAKING
Click to view session |
C. PROGRAMMATIC CONSIDERATIONS IN HEALTHCARE AND THEIR IMPACT ON HEALTH OUTCOMES
Click to view session |
| 1:00 - 1:15 |
A-1 (AHE) 10/18- PRESENTATION CANCELLED - HOSPITALIZATIO..
A-1 (AHE) 10/18- PRESENTATION CANCELLED - HOSPITALIZATION COSTS ASSOCIATED WITH ATRIAL FIBRILLATION FOR PATIENTS OF ISCHEMIC STROKE IN THE UNITED STATES
|
B-1 (DEC) DOES BIOMARKER INFORMATION IMPACT BREAST..
B-1 (DEC) DOES BIOMARKER INFORMATION IMPACT BREAST CANCER PATIENTS' PREFERENCES FOR THERAPY?
|
C-1* (HSP) SYNERGIES IN OUTCOMES FROM PUBLIC AND PRIVATE..
C-1* (HSP) SYNERGIES IN OUTCOMES FROM PUBLIC AND PRIVATE SECTOR TB AND MDR TB CONTROL INTERVENTIONS: AN INDIAN MICROSIMULATION MODELING STUDY
|
| 1:15 - 1:30 |
A-2* (AHE) INCREMENTAL HEALTHCARE COSTS OF ANXIETY..
A-2* (AHE) INCREMENTAL HEALTHCARE COSTS OF ANXIETY DISORDERS IN THE AMBULATORY ADULT POPULATION OF THE UNITED STATES
|
B-2 (DEC) UNDERSTANDING PREFERENCES FOR CRC SCREENING..
B-2 (DEC) UNDERSTANDING PREFERENCES FOR CRC SCREENING PROGRAMS AMONG VULNERABLE ADULTS IN RURAL NORTH CAROLINA: A DISCRETE CHOICE EXPERIMENT
|
C-2* (HSP) UNEMPLOYMENT AND HEALTH OUTCOMES: MEDICARE'S..
C-2* (HSP) UNEMPLOYMENT AND HEALTH OUTCOMES: MEDICARE'S IMPACT ON THE US HEALTHCARE INDUSTRY
|
| 1:30 - 1:45 |
A-3 (HSP) CHARACTERISTICS OF MULTI-DISCIPLINARY HEART..
A-3 (HSP) CHARACTERISTICS OF MULTI-DISCIPLINARY HEART FAILURE CLINICS THAT PREDICT 1-YEAR CUMULATIVE HEALTH CARE COSTS: A POPULATION-BASED STUDY
|
B-3 (DEC) EFFECT OF A PATIENT DECISION AID FOR PROSTATE..
B-3 (DEC) EFFECT OF A PATIENT DECISION AID FOR PROSTATE CANCER ON DIFFERENT ASPECTS OF REGRET: A RANDOMIZED, CONTROLLED TRIAL
|
C-3* (HSP) EXPANDING THE NORWEGIAN HPV VACCINE PROGRAM TO..
C-3* (HSP) EXPANDING THE NORWEGIAN HPV VACCINE PROGRAM TO INCLUDE BOYS
|
| 1:45 - 2:00 |
A-4 (AHE) TOTAL HEALTH CARE EXPENDITURES ASSOCIATED WITH..
A-4 (AHE) TOTAL HEALTH CARE EXPENDITURES ASSOCIATED WITH OBESITY-RELATED DISEASES: USING DATA FROM THE NATIONAL HEALTH INTERVIEW SURVEY 1997-2000 AND THE MEDICAL EXPENDITURE PANEL SURVEY
|
B-4* (DEC) GOAL SETTING DURING PERIODIC HEALTH EXAMS:..
B-4* (DEC) GOAL SETTING DURING PERIODIC HEALTH EXAMS: WHAT TYPES OF GOALS ARE SET AND WHAT IMPACT DOES IT HAVE ON THE VISIT?
|
C-4 (HSP) COST-EFFECTIVENESS OF ROUTINE CARDIAC..
C-4 (HSP) COST-EFFECTIVENESS OF ROUTINE CARDIAC ASSESSMENT FOR CHILDHOOD CANCER SURVIVORS: A MODEL-BASED EXPLORATION OF THE IMPACT OF RECOMMENDED GUIDELINES ON LONG-TERM OUTCOMES AND SURVIVAL
|
| 2:00 - 2:15 |
A-5 (AHE) WHY THE NATIONAL INSTITUTE FOR HEALTH AND CARE..
A-5 (AHE) WHY THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE'S NEW GUIDANCE ON DISCOUNTING CREATES SCOPE FOR AGE DISCRIMINATION AND OTHER INCONSISTENCIES
|
B-5 (HSP) PHYSICIAN DECISION-MAKING AND TRENDS IN USE OF..
B-5 (HSP) PHYSICIAN DECISION-MAKING AND TRENDS IN USE OF CARDIAC STRESS TESTING TO DIAGNOSE CORONARY HEART DISEASE IN THE UNITED STATES
|
C-5 (HSP) DO WE NEED COMPARATIVE EFFECTIVENESS RESEARCH..
C-5 (HSP) DO WE NEED COMPARATIVE EFFECTIVENESS RESEARCH ON THE NEW ORAL ANTICOAGULANTS?
|
| 2:30 - 3:45 PM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 8,11,12 |
Key Ballroom 7,9,10 |
Key Ballroom 3-4 |
| Session Title |
D. CANCER SCREENING IN WOMEN'S HEALTH: CAN IT BE IMPROVED?
Click to view session |
E. IDENTIFYING THE CHALLENGES TO UNDERSTANDING EVIDENCE AND DECISIONS
Click to view session |
F. COMPLEX DISEASE MODELING: METHODS AND APPLICATIONS
Click to view session |
| 2:30 - 2:45 |
D-1 (HSP) CERVICAL CANCER SCREENING IN RESOURCE-LIMITED..
D-1 (HSP) CERVICAL CANCER SCREENING IN RESOURCE-LIMITED SETTINGS: EVALUATING TRADEOFFS BETWEEN TEST PERFORMANCE AND PROGRAMMATIC CONSIDERATIONS
|
E-1 (DEC) CLINICIAN TRAINING: A CRITICAL COMPONENT FOR..
E-1 (DEC) CLINICIAN TRAINING: A CRITICAL COMPONENT FOR IMPLEMENTATION OF PATIENT DECISION AIDS
|
F-1* (MET) BAYESIAN LEARNING MODELS FOR ADAPTIVE..
F-1* (MET) BAYESIAN LEARNING MODELS FOR ADAPTIVE TREATMENT DECISIONS IN THE PRESENCE OF NOISY FEEDBACK AND TREATMENT-DEPENDENT RATE OF RELAPSES: AN APPLICATION TO MULTIPLE SCLEROSIS
|
| 2:45 - 3:00 |
D-2 (HSP) THE BENEFIT-HARM FRONTIER OF HPV PRIMARY..
D-2 (HSP) THE BENEFIT-HARM FRONTIER OF HPV PRIMARY SCREENING FOR CERVICAL CANCER IN GERMANY: ESTIMATES FROM A SYSTEMATIC DECISION -ANALYSIS
|
E-2 (DEC) INCORPORATING SHARED DECISION MAKING AS PART..
E-2 (DEC) INCORPORATING SHARED DECISION MAKING AS PART OF PERFORMANCE MEASUREMENT: THE CHALLENGE OF TIMING
|
F-2 (MET) MODELING HIV TRANSMISSION DYNAMICS IN..
F-2 (MET) MODELING HIV TRANSMISSION DYNAMICS IN CONJUNCTION WITH A MICROSIMULATION OF DISEASE PROGRESSION
|
| 3:00 - 3:15 |
D-3* (HSP) DOUBLE READING OF MAMMOGRAMS: EFFECTIVELY..
D-3* (HSP) DOUBLE READING OF MAMMOGRAMS: EFFECTIVELY PAIRING READERS WITH DIVERSE SKILLS TO IMPROVE PERFORMANCE
|
E-3 (DEC) SHORT GRAPH LITERACY SCALE
E-3 (DEC) SHORT GRAPH LITERACY SCALE
|
F-3 (MET) CALIBRATION OF A MARKOV CARDIOVASCULAR DISEASE..
F-3 (MET) CALIBRATION OF A MARKOV CARDIOVASCULAR DISEASE MICROSIMULATION MODEL USING AN ESTABLISHED CELL-BASED SIMULATION MODEL
|
| 3:15 - 3:30 |
D-4 (HSP) THE EFFECT OF DIFFERENT UTILITY ASSUMPTIONS ON..
D-4 (HSP) THE EFFECT OF DIFFERENT UTILITY ASSUMPTIONS ON THE COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING
|
E-4* (DEC) HOW SHOULD COMPLEX DATA BE PRESENTED TO HELP..
E-4* (DEC) HOW SHOULD COMPLEX DATA BE PRESENTED TO HELP PATIENTS MAKE INFORMED DECISIONS?
|
F-4 (MET) HARNESSING THE POWER OF BAYESIAN STATISTICS..
F-4 (MET) HARNESSING THE POWER OF BAYESIAN STATISTICS AND PATIENT-LEVEL DATA TO PREDICT THE EFFECTIVENESS OF IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) THERAPY IN PATIENT SUBGROUPS
|
| 3:30 - 3:45 |
D-5* (HSP) MODELLING THE OCCURRENCE OF INVASIVE BREAST..
D-5* (HSP) MODELLING THE OCCURRENCE OF INVASIVE BREAST CANCER IN WOMEN AGED 50-59 AND SIMULATING THE STUDY AND CONTROL GROUPS OF WOMEN IN THE CANADIAN NATIONAL BREAST SCREENING STUDY-2
|
E-5 (DEC) ABILITY TO IDENTIFY OUT-OF-RANGE TEST RESULTS..
E-5 (DEC) ABILITY TO IDENTIFY OUT-OF-RANGE TEST RESULTS IN STANDARD TABLES IS HIGHLY DEPENDENT ON NUMERACY
|
F-5 (MET) BIG DATA TOOLS AND LARGE-SCALE SIMULATION..
F-5 (MET) BIG DATA TOOLS AND LARGE-SCALE SIMULATION MODELS: A PLATFORM FOR INTERACTIVE HYPOTHESIS GENERATION
|
| Tuesday, October 22, 2013, Day Two |
| 10:30 - 12:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 5-6 |
Key Ballroom 8,11,12 |
Key Ballroom 7,9,10 |
| Session Title |
G. APPLICATION OF COST EFFECTIVENESS ANALYSES: FROM PREVENTION TO TREATMENT
Click to view session |
H. METHODS FOR OPTIMIZING AND ANALYZING PATIENT OUTCOMES
Click to view session |
I. MODEL INPUTS: HOW CAN WE CHOOSE THE BEST ONES?
Click to view session |
| 10:30 - 10:45 |
G-1* (AHE) COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED..
G-1* (AHE) COST-EFFECTIVENESS OF PROCALCITONIN-GUIDED ANTIBIOTIC THERAPY FOR OUTPATIENT MANAGEMENT OF ACUTE RESPIRATORY TRACT INFECTIONS IN ADULTS
|
H-1 (MET) HETEROGENEITY AND HEALTH OUTCOMES USING..
H-1 (MET) HETEROGENEITY AND HEALTH OUTCOMES USING COHORT- AND INDIVIDUAL-BASED MODELS
|
I-1 (MET) SELECTING BEST-FITTING INPUTS IN MUTLI-TARGET..
I-1 (MET) SELECTING BEST-FITTING INPUTS IN MUTLI-TARGET MODEL CALIBRATION AND IMPLICATIONS FOR COST-EFFECTIVENESS ANALYSIS
|
| 10:45 - 11:00 |
G-2 (AHE) COST-EFFECTIVENESS OF UNICOMPARTMENTAL VS..
G-2 (AHE) COST-EFFECTIVENESS OF UNICOMPARTMENTAL VS TOTAL KNEE ARTHROPLASTY IN OLDER AND YOUNGER PATIENTS IN THE UNITED STATES
|
H-2 (HSP) ADHERENCE TO PREVENTIVE PRACTICES AND..
H-2 (HSP) ADHERENCE TO PREVENTIVE PRACTICES AND PROJECTED POPULATION IMPACT OF HEALTH SYSTEM INTERVENTIONS FOR CORONARY HEART DISEASE
|
I-2 (MET) ESTIMATING THE CLINICAL AND QUALITY OF LIFE..
I-2 (MET) ESTIMATING THE CLINICAL AND QUALITY OF LIFE BENEFITS OF ACUPUNCTURE FROM MULTIPLE PATIENT LEVEL DATA SOURCES: WHAT A PAIN!
|
| 11:00 - 11:15 |
G-3* (AHE) COST-EFFECTIVENESS OF SAME-DAY DISCHARGE AFTER..
G-3* (AHE) COST-EFFECTIVENESS OF SAME-DAY DISCHARGE AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
|
H-3 (HSP) COMPARING SURGICAL PERFORMANCE FOR ESOPHAGECTO..
H-3 (HSP) COMPARING SURGICAL PERFORMANCE FOR ESOPHAGECTOMY: HOW LONG SHOULD WE FOLLOW-UP?
|
I-3* (MET) CHANGING CYCLE LENGTHS IN DISCRETE-TIME MARKOV..
I-3* (MET) CHANGING CYCLE LENGTHS IN DISCRETE-TIME MARKOV MODELS: CHALLENGES AND SOLUTIONS
|
| 11:15 - 11:30 |
G-5 (AHE) COST-EFFECTIVENESS ANALYSIS OF THE NATIONAL..
G-5 (AHE) COST-EFFECTIVENESS ANALYSIS OF THE NATIONAL PERINATAL HEPATITIS B PREVENTION PROGRAM
|
H-4 (HSP) ADALIMUMAB VERSUS INFLIXIMAB FOR THE TREATMENT..
H-4 (HSP) ADALIMUMAB VERSUS INFLIXIMAB FOR THE TREATMENT OF MODERATE TO SEVERE ULCERATIVE COLITIS IN ADULT PATIENTS WITH NO PRIOR ANTI-TNF EXPERIENCE: AN INDIRECT COMPARISON META-ANALYSIS
|
I-4 (MET) STRATEGIES FOR CALCULATING EVPPI EFFICIENTLY
I-4 (MET) STRATEGIES FOR CALCULATING EVPPI EFFICIENTLY
|
| 11:30 - 11:45 |
G-6 (AHE) USING A MODEL-BASED ECONOMIC EVALUATION IN A..
G-6 (AHE) USING A MODEL-BASED ECONOMIC EVALUATION IN A FEASIBILITY STUDY TO INFORM THE VALUE OF A FUTURE TRIAL: A CASE STUDY OF GROMMETS-INSERTION FOR CHILDREN WITH CLEFT PALATE AFFECTED BY OTITIS MEDIA WITH EFFUSION
|
H-5* (MET) LOGISTIC REGRESSION WITH FILTERED DATA TO..
H-5* (MET) LOGISTIC REGRESSION WITH FILTERED DATA TO IMPROVE PROGRESSION IDENTIFICATION
|
I-5 (MET) SET-VALUED DYNAMIC TREATMENT REGIMES FOR..
I-5 (MET) SET-VALUED DYNAMIC TREATMENT REGIMES FOR COMPETING OUTCOMES
|
| 11:45 - 12:00 |
|
H-6* (HSP) FRESH VERSUS ELECTIVE FROZEN-THAWED EMBRYO..
H-6* (HSP) FRESH VERSUS ELECTIVE FROZEN-THAWED EMBRYO TRANSFER FOR WOMEN UNDERGOING IN VITRO FERTILIZATION: A DECISION ANALYSIS
|
I-6 (MET) USING PROJECTIONS OF LIFE EXPECTANCY IN..
I-6 (MET) USING PROJECTIONS OF LIFE EXPECTANCY IN ECONOMIC DECISION MAKING
|
| 1:30 - 3:00 PM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 5-6 |
Key Ballroom 8,11,12 |
Key Ballroom 7,9,10 |
| Session Title |
J. IMPROVING DECISIONS FOR CANCER CARE
Click to view session |
K. WELL THAT WAS HARD…DECISION MAKING IN COMPLEX CLINICAL ENCOUNTERS
Click to view session |
L. USING MODELING TO MAKE BETTER MEDICAL DECISIONS
Click to view session |
| 1:30 - 1:45 |
J-1 (DEC) RACIAL DIFFERENCES IN TREATMENT PREFERENCES..
J-1 (DEC) RACIAL DIFFERENCES IN TREATMENT PREFERENCES AFTER USING A LOW VERSUS HIGH LITERACY PROSTATE CANCER DECISION AID
|
K-1 (DEC) "WHAT WOULD YOU DO?": OBSTETRICIANS' AND..
K-1 (DEC) "WHAT WOULD YOU DO?": OBSTETRICIANS' AND NEONATOLOGISTS' RESPONSES TO STANDARDIZED PATIENT REQUESTS FOR ADVICE REGARDING WHETHER TO ATTEMPT NEONATAL RESUSCITATION AT 23 WEEKS GESTATION
|
L-1 (AHE) 10/19- PRESENTATION CANCELED. EXTENDING..
L-1 (AHE) 10/19- PRESENTATION CANCELED. EXTENDING THE METHODS FOR THE ANALYSIS OF (AND MAPPING BETWEEN) PATIENT REPORTED OUTCOME MEASURES
|
| 1:45 - 2:00 |
J-2 (DEC) CANCER SCREENING DECISIONS: THE IMPACT OF THE..
J-2 (DEC) CANCER SCREENING DECISIONS: THE IMPACT OF THE AFFECT HEURISTIC IN INTERPRETATION OF TEST RISKS AND BENEFITS
|
K-2 (DEC) PARENTS' EXPECTATION TO RECEIVE ANTIBIOTIC..
K-2 (DEC) PARENTS' EXPECTATION TO RECEIVE ANTIBIOTIC PRESCRIPTIONS FOR CHILDREN
|
L-2* (MET) DYNAMIC ABANDON/EXTRACT DECISIONS FOR FAILED..
L-2* (MET) DYNAMIC ABANDON/EXTRACT DECISIONS FOR FAILED CARDIAC LEADS
|
| 2:00 - 2:15 |
J-3 (DEC) ADDING NATURAL FREQUENCY DATA TO A DECISION..
J-3 (DEC) ADDING NATURAL FREQUENCY DATA TO A DECISION AID FOR COLORECTAL CANCER SCREENING: RESULTS OF A RANDOMIZED TRIAL
|
K-3 (DEC) CAN THE IMPORTANCE OF HERD IMMUNITY INFLUENCE..
K-3 (DEC) CAN THE IMPORTANCE OF HERD IMMUNITY INFLUENCE PARENTS' INTENTIONS TO VACCINATE THEIR CHILDREN?
|
L-3 (MET) OPTIMAL DESIGN OF NEW RESEARCH WHEN THERE ARE..
L-3 (MET) OPTIMAL DESIGN OF NEW RESEARCH WHEN THERE ARE MULTIPLE COMPETING HEALTH TECHNOLOGIES: HOW MANY ARMS, AND WHICH TREATMENTS?
|
| 2:15 - 2:30 |
J-4 (DEC) DECISION REGRET FOLLOWING TREATMENT FOR..
J-4 (DEC) DECISION REGRET FOLLOWING TREATMENT FOR LOCALIZED BREAST CANCER: IS REGRET STABLE OVER TIME?
|
K-4 (DEC) SUPPORTING PATIENT VALUES: A SYSTEMATIC REVIEW..
K-4 (DEC) SUPPORTING PATIENT VALUES: A SYSTEMATIC REVIEW OF VALUES CLARIFICATION EXERCISES
|
L-4 (MET) METHODS FOR THE JOINT META-ANALYSIS OF..
L-4 (MET) METHODS FOR THE JOINT META-ANALYSIS OF MULTIPLE TESTS
|
| 2:30 - 2:45 |
J-5 (DEC) DOES FRAMING OF CANCER SURVIVAL AFFECT..
J-5 (DEC) DOES FRAMING OF CANCER SURVIVAL AFFECT PERCEIVED VALUE OF CARE? COMPARING RESPONDENTS WITH AND WITHOUT CANCER
|
K-5 (DEC) SUBJECTIVE AND PHYSIOLOGICAL EMOTIONAL..
K-5 (DEC) SUBJECTIVE AND PHYSIOLOGICAL EMOTIONAL RESPONSES WHILE READING PATIENTS' NARRATIVES ABOUT COLORECTAL CANCER SCREENING
|
L-5* (MET) IMPROVING BIOPSY RECOMMENDATIONS FOLLOWING..
L-5* (MET) IMPROVING BIOPSY RECOMMENDATIONS FOLLOWING MAMMOGRAPHY USING RANDOM FORESTS
|
| 2:45 - 3:00 |
J-6 (DEC) CHARACTERIZING SURGICAL TREATMENT DECISION..
J-6 (DEC) CHARACTERIZING SURGICAL TREATMENT DECISION INVOLVEMENT IN YOUNG WOMEN WITH BREAST CANCER
|
K-6 (DEC) FAITH IN DELIBERATION: ON THE IMPACT OF..
K-6 (DEC) FAITH IN DELIBERATION: ON THE IMPACT OF DELIBERATIVE VERSUS INTUITIVE STRATEGIES ON PATIENT DECISIONS
|
L-6* (MET) MEASURING DECISION SENSITIVITY WITH MULTINOMIA..
L-6* (MET) MEASURING DECISION SENSITIVITY WITH MULTINOMIAL LOGISTIC REGRESSION METAMODELING
|
| Wednesday, October 23, 2013, Day Three |
| 10:00 - 11:30 AM |
Attendees are invited to move from room-to-room |
| Room |
Key Ballroom 8,11,12 |
Key Ballroom 7,9,10 |
Key Ballroom 3-4 |
| Session Title |
M. TRIALS AND INTERVENTIONS FOR RISK REDUCTION
Click to view session |
N. RESOURCES FOR THE FUTURE: PLANNING THE COSTS OF HEALTH CARE
Click to view session |
O. ON THE FRONTIER: ADVANCES IN METHODS RELEVANT TO COST-EFFECTIVENESS
Click to view session |
| 10:00 - 10:15 |
M-1 (DEC) ACCEPTABILITY AND EFFICACY OF A SYSTEMATIC..
M-1 (DEC) ACCEPTABILITY AND EFFICACY OF A SYSTEMATIC SMOKING CESSATION INTERVENTION USING MOTIVATIONAL INTERVIEWING FOR SMOKERS HOSPITALIZED FOR ACUTE CORONARY SYNDROMES
|
N-1* (DEC) THE EFFECT OF THE DIFFUSION OF THE SURGICAL..
N-1* (DEC) THE EFFECT OF THE DIFFUSION OF THE SURGICAL ROBOT ON THE HOSPITAL-LEVEL UTILIZATION OF PARTIAL NEPHRECTOMY
|
O-1 (AHE) OPTIMAL INFORMATION ACQUISITION POLICIES WITH..
O-1 (AHE) OPTIMAL INFORMATION ACQUISITION POLICIES WITH PARAMETERS THAT VARY ACROSS INTERVENTION COHORTS: APPLICATION TO HCV SCREENING
|
| 10:15 - 10:30 |
M-2 (DEC) GENERAL PRACTITIONERS' USE OF ABSOLUTE RISK..
M-2 (DEC) GENERAL PRACTITIONERS' USE OF ABSOLUTE RISK VERSUS INDIVIDUAL RISK FACTORS IN CARDIOVASCULAR DISEASE PREVENTION: AN EXPERIMENTAL STUDY
|
N-2* (AHE) HOSPITAL RESOURCE USE IN CHRONIC DISEASE..
N-2* (AHE) HOSPITAL RESOURCE USE IN CHRONIC DISEASE COMBINATIONS: IS IT ENOUGH TO JUST ADD THEM UP?
|
O-2 (AHE) ESTIMATING A COST EFFECTIVENESS THRESHOLD TO..
O-2 (AHE) ESTIMATING A COST EFFECTIVENESS THRESHOLD TO REFLECT OPPORTUNITY COSTS: THE CASE OF NICE IN THE UK
|
| 10:30 - 10:45 |
M-3 (AHE) DEVELOPMENT OF A WEB-BASED SIMULATION TOOL TO..
M-3 (AHE) DEVELOPMENT OF A WEB-BASED SIMULATION TOOL TO MODEL COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS IN CHRONIC HEART FAILURE
|
N-3 (AHE) EFFECT OF MAGNITUDE OF WEIGHT LOSS ON ANNUAL..
N-3 (AHE) EFFECT OF MAGNITUDE OF WEIGHT LOSS ON ANNUAL ANTIHYPERTENSIVE, LIPID-LOWERING, AND ANTIDIABETIC MEDICATION COST IN OBESE AND OVERWEIGHT INDIVIDUALS
|
O-3 (AHE) MAKING THE MOST OF LIMITED DATA WITH..
O-3 (AHE) MAKING THE MOST OF LIMITED DATA WITH UNCERTAINTY USING PROBABILISTIC ANALYSES: A CASE STUDY IN ONCOLOGY
|
| 10:45 - 11:00 |
M-4 (DEC) HOW QUANTITATIVE RISK-REDUCTION INFORMATION..
M-4 (DEC) HOW QUANTITATIVE RISK-REDUCTION INFORMATION INFLUENCES VACCINATION INTENTIONS: THE MEDIATING EFFECT OF MESSAGE CREDIBILITY
|
N-4 (AHE) TREAT, TEST, OR NEITHER? COST-EFFECTIVENESS OF..
N-4 (AHE) TREAT, TEST, OR NEITHER? COST-EFFECTIVENESS OF CEREBROVASCULAR RESERVE IMAGING TO GUIDE TREATMENT OF CAROTID STENOSIS FOR STROKE PREVENTION
|
O-4 (AHE) EXPANDING THE RANGE OF COMPARATORS FOR..
O-4 (AHE) EXPANDING THE RANGE OF COMPARATORS FOR COST-EFFECTIVENESS ANALYSES OF VACCINES: THE EXAMPLE OF A POTENTIAL GROUP B STREPTOCOCCAL (GBS) VACCINE PROGRAM FOR PREGNANT WOMEN IN SOUTH AFRICA
|
| 11:00 - 11:15 |
M-5 (DEC) A PILOT RANDOMIZED CONTROLLED TRIAL OF..
M-5 (DEC) A PILOT RANDOMIZED CONTROLLED TRIAL OF PERSONALIZED DECISION SUPPORT FOR OLDER PATIENTS WITH DIABETES
|
N-5 (HSP) THE IMPACT OF STATE HIV POLICY ON CLINICAL AND..
N-5 (HSP) THE IMPACT OF STATE HIV POLICY ON CLINICAL AND ECONOMIC OUTCOMES
|
O-5 (AHE) A COST-EFFECTIVENESS ANALYSIS OF TWO..
O-5 (AHE) A COST-EFFECTIVENESS ANALYSIS OF TWO PATIENT-LEVEL REMINDER INTERVENTIONS TO INCREASE ADHERENCE TO HAART AMONG HIV PATIENTS IN MEXICO
|
| 11:15 - 11:30 |
M-6 (DEC) RISK COMMUNICATION USING ABSOLUTE RISK..
M-6 (DEC) RISK COMMUNICATION USING ABSOLUTE RISK REDUCTION OR PROLONGATION OF LIFE: DOES IT INFLUENCE REAL LIFE DECISIONS ABOUT CHOLESTEROL LOWERING MEDICATION?
|
N-6 (HSP) THE HEPATITIS C DRUG PIPELINE: COLLABORATION..
N-6 (HSP) THE HEPATITIS C DRUG PIPELINE: COLLABORATION BETWEEN ACADEMIC AND HTA AGENCY PARTNERS TO DEVELOP AN EARLY ECONOMIC MODEL
|
O-6* (MET) EXPECTED VALUE OF SAMPLE INFORMATION FOR..
O-6* (MET) EXPECTED VALUE OF SAMPLE INFORMATION FOR CORRELATED DATA: A PRACTICAL APPROACH
|
